최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기동의신경정신과학회지 = Journal of oriental neuropsychiatry, v.31 no.1, 2020년, pp.25 - 38
이재은 (부산대학교 한의학전문대학원) , 김상호 (대구한의대부속 포항한방병원 한방신경정신과) , 김보경 (부산대학교 한의학전문대학원 한방신경정신과교실) , 임정화 (부산대학교 한의학전문대학원 한방신경정신과교실)
Objectives: This review aimed to investigate the effectiveness of Chai-Hu-Shu-Gan-San (CHSGS) for treatment of insomnia. Methods: 9 databases were comprehensively searched from their inception dates until Jan 2020 using keywords like Insomnia, Chai-Hu-Shu-Gan-San and Sihosogan-san. We included rando...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
불면장애는 어떨 때 진단되는가? | 불면은 수면을 취할 수 있는 적절한 기회와 환경이 주어졌음에도 불구하고 잠들기 어렵거나 수면을 유지하기 힘들거나 이른 아침에 깨어 다시 잠들기 어려워 양적으로나 질적으로 수면이 만족스럽지 못한 것으로 정의된다1,2). 정신장애의 진단 및 통계 편람 5판(Diagnostic and statistical manual of mental disorders 5th edition, DSM-5)에 의하면 위와 같은 수면의 양적, 질적인 불만족이 일주일에 적어도 3회 이상 발생하고 3개월 이상 지속될 때 불면장애로진단한다3). | |
불면이란 무엇인가? | 불면은 수면을 취할 수 있는 적절한 기회와 환경이 주어졌음에도 불구하고 잠들기 어렵거나 수면을 유지하기 힘들거나 이른 아침에 깨어 다시 잠들기 어려워 양적으로나 질적으로 수면이 만족스럽지 못한 것으로 정의된다1,2). 정신장애의 진단 및 통계 편람 5판(Diagnostic and statistical manual of mental disorders 5th edition, DSM-5)에 의하면 위와 같은 수면의 양적, 질적인 불만족이 일주일에 적어도 3회 이상 발생하고 3개월 이상 지속될 때 불면장애로진단한다3). | |
불면 치료법 중 약물치료의 한계점은 무엇인가? | 서양의학의 대표적인 불면 치료법은 약물치료와 인지행동치료(Cognitive behavioral therapy for insomnia, CBT-I)이다. 약물치료는 단기간 효과는 우수하지만, 장기복용의 효과에 대한 근거가 불충분하며 남용, 의존 및 두통, 피로감, 구토 등의 부작용이 발생할 수 있다는 한계점이 있다6,7). 불면에 사용되는 대표적인 비약물치료인 CBT-I 경우, 그 시행에 시간과 비용이 많이 요구되고 불면장애 환자의 20%정도는 치료에 반응하지 않으며 치료 후에도 39∼44%의 환자에서 치료효과가 지속되지 않다는 보고가 있어8-10),임상에서 활용하기에 어려움이 있다. |
American Academy of Sleep Medicine. The international classification of sleep disorders: diagnostic & coding manual. 2nd ed. Westchester: American Academy of Sleep Medicine 2005.
National Institutes of Health. NIH State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults statement. J Clin Sleep Med 2005;1(4):412-21.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington DC: American Psychiatric Publishing 2013:361-422.
Cho YW, Shin WC, Yun CH, Hong SB, Kim J, Earley CJ. Epidemiology of insomnia in korean adults: prevalence and associated factors. J Clin Neurol. 2009;5(1):20-3. doi: 10.3988/jcn.2009.5.1.20.
Ministry of Health and Welfare. Statistics for Insomnia. Available from:URL:http://opendata.hira.or.kr/op/opc/olap-MfrnIntrsIlnsInfo.do
Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, Klassen TP, Witmans M. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med. 2007;22(9):1335-50. doi: 10.1007/s11606-007-0251-z.
Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs. 2014;28(9):799-816. doi: 10.1007/s40263-014-0198-7.
Harvey AG. A cognitive model of insomnia. Behav Res Ther. 2002;40(8):869-93. doi: 10.1016/s0005-7967(01)00061-4.
Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151(8):1172-80. doi: 10.1176/ajp.151.8.1172.
Morin CM, Vallieres A, Guay B, Ivers H, Savard J, Merette C, Bastien C, Baillargeon L. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. Jama. 2009;301(19):2005-15. doi: 10.1001/jama.2009.682.
Lim JH, Jeong JH, Kim SH, Kim KO, Lee SY, Lee SH, Kim BK. The Pilot Survey of the Perception on the Practice Pattern, Diagnosis, and Treatment on Korean Medicine Insomnia: Focusing on the Difference between Korean Medical Neuropsychiatry Specialists and Korean Medical General Practitioners. Evid Based Complement Alternat Med. 2018;2018:9152705. doi: 10.1155/2018/9152705.
The Text Compilation Committee of National Oriental Medicine University of Oriental Neuropsychology 3rd edition. Oriental Neuropsychology. Seoul:Jipmoondang. 2016:239-40.
TCM clinical guideline of insomnia research group(WHO/WPO). Guidelines of clinical practice of insomnia in Chinese medicine. World Journal of sleep Medicine 2016;3(1):8-25.
Korean medical Prescription Professors. Korean medical Prescription. Seoul: Yonglimsa. 2006:157.
Rueda DC, Zaugg J, Quitschau M, Reich E, Hering S, Hamburger M. Discovery of GABA(A) receptor modulator aristolactone in a commercial sample of the Chinese herbal drug "Chaihu" (Bupleurum chinense roots) unravels adulteration by nephrotoxic Aristolochia manshuriensis roots. Planta Med. 2012;78(3):207-10.
Ito A, Shin N, Tsuchida T, Okubo T, Norimoto H. Antianxietylike effects of Chimpi (dried citrus peels) in the elevated open-platform test. Molecules. 2013;18(8):10014-23.
Qiu ZK, He JL, Liu X, Zeng J, Chen JS, Nie H. Anti-PTSDlike effects of albiflorin extracted from Radix paeoniae Alba. Journal of Ethnopharmacology. 2017;198:324-330.
Park JH, Lee GH, Lee JT. Effect of methanol extract of cnidii rhizoma on the function of receptors for GABA and glycine. Journal of the Korean Academy of Pediatric Dentistry. 2005;32(1):55-66.
Hoffmann KM, Beltran L, Ziemba PM, Hatt H, Gisselmann G. Potentiating effect of glabridin from Glycyrrhiza glabra on GABAA receptors. Biochem Biophys Rep. 2016;6:197-202.
Wang CL, Gao J, Zhang BL, Zhang RS, Wang C, Li XY, Du HG, Zhou CK, Fang SK. The efficacy and safety of Chai Hu Shu Gan San as an adjuvant drug for selective serotonin reuptake inhibitors in the treatment of post-stroke depression: A meta-analysis. Neurology Asia. 2019;24(3):215-27.
Sun Y, Xu X, Zhang JP, Chen YY. Treatment of depression with Chai Hu Shu Gan San: a systematic review and meta-analysis of 42 randomized controlled trials. BMC Complement Altern Med. 2018;18(1):66. doi: 10.1186/s12906-018-2130-z.
Qin F, Liu JY, Yuan JH. Chaihu-Shugan-San, an oriental herbal preparation, for the treatment of chronic gastritis: a meta-analysis of randomized controlled trials. J Ethnopharmacol. 2013;146(2):433-9. doi: 10.1016/j.jep.2013.01.029.
Yang N, Jiang XH, Qiu XL, Hu ZQ, Wang L, Song MX. Modified Chaihu Shugan Powder for Functional Dyspepsia: Meta-Analysis for Randomized Controlled Trial. Evid Based Complement Alternat Med. 2013;2013:791724. doi: 10.1155/2013/791724.
Park MY, Kim DJ, Choi HY, Kim JD. A Clinical Process Report on the Patient Suffered from Flank Pain after CVA Treated with Shihosogansan. Korean J. Orient. Int Med. 2003;24(1):144-50.
Jung MH, Lee TH. Anti-stress effects of Sihosogansan in the passive avoidance test and the forced swimming test. Kor. J. Herbology. 2007;22(2):127-35.
Jo OH, Jung WS, Seo YJ, Cho HB. Shihosogansangamibang induced Apoptosis in Human Cervical Carcinoma HeLa Cells. he Journal of Oriental Obstetrics&Gynecology. 2004;17(4):101-11.
Ahn SJ, Lee TH. Effect of Chaihushugansan and Chaihuyigantang on the change of Monoamine Contents in the Hypothalamus of Mice induced by the Immobilization Stress. the Korean journal of oriental medical prescription. 2003;11(01):099-114.
Review Manager (RevMan) Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Qian HF. Observation on the effect of integrated traditional Chinese and western medicine on insomnia. China Modern Doctor. 2007;45(18):72-88.
Fu QF. ChaihuShugan Powder Modified for 60 Cases of Refractory Insomnia. Jiangxi Journal of Traditional Chinese Medicine. 2012;43(352):39-40.
Ding L WZ, Liang J, Tang M. Clinical study of Chaihushugansan combined with doxepin in treating insomnia liver qi stagnation type. Guangming Journal of Chinese Medicine. 2015;30(6):1199-201.
Yang DF CL. Clinical Observation on Modified ChaiHu ShuGan Powder in Treating Insomnia of Liver-Qi Stagnation Pattern. Western Journal of Traditional Chinese Medicine. 2015;28(11):82-4.
Wang S, Hu S, Zhang C, Qiu J, Li Y. Antidepressant-like activity of Chaihu-Shugan-San aqueous extract in rats and its possible mechanism. Pharmacogn Mag. 2014;10(Suppl 1):S50-6. doi: 10.4103/0973-1296.127342.
Wang S, Hu S, Zhang C, Qiu J, Li Y. Effect of Chaihu Shugan San and its components on expression of ERK1/2 mRNA in the hippocampus of rats with chronic mild unpredicted stress depression. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36(2):93-100. doi: 10.3969/j.issn.1672-7347.2011.02.001.
Qiu J, Hu SY, Zhang CH, Shi GQ, Wang SE, Xiang T. The effect of Chaihu-Shugan-San and its components on the expression of ERK5 in the hippocampus of depressed rats. J Ethnopharmacol. 2014;152(2):320-6. doi: 10.1016/j.jep.2014.01.004.
The Korean Society Of Oriental Neuropsychiatry. Korean Medicine Clinical Practice Guideline for Insomnia Disorders (preliminary certification). 2017.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.